- Home
- » Tags
- » Ruxolitinib
Top View
- Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
- WHO Drug Information Vol
- OHC Clinical Trials List 11-14
- Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid- Derived Hematologic Malignancies
- United States Securities and Exchange Commission Form 10-K Incyte Corporation
- Ruxolitinib in Combination with Prednisone and Nilotinib Exhibit Synergistic Effects in Human Cells Lines and Primary Cells from Myeloproliferative Neoplasms
- View Annual Report
- RMD Commentary, JAK Kinase Inhibitors: a Preferred Alternative to TNF Inhibitors?
- 2019 Prescrire Drug Awards
- Filgotinib Suppresses HIV-1–Driven Gene Transcription by Inhibiting HIV-1 Splicing and T Cell Activation
- Ruxolitinib-For-Myelofibrosis.Pdf
- Jakavi, INN-Ruxolitinib
- Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance–Pharmacodynamic Study
- JAK2 Is a Therapeutic Target in Myeloproliferative Neoplasms (2014)
- ATC/DDD Classification (Final)
- Oncofocus® Precision Oncology
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Ruxolitinib Combined with Vorinostat Suppresses Tumor Growth and Alters Metabolic Phenotype in Hematological Diseases
- The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Study Protocol);
- Mechanisms of Action of Emerging Agents in GVHD
- Specialty Pipeline MONTHLY UPDATE
- Specificity and Mechanism-Of-Action of the JAK2 Tyrosine Kinase Inhibitors
- 1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
- Persistence of Myelofibrosis Treated with Ruxolitinib
- Full Prescribing Information for JAKAFI
- JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Final Policy Recommendations
- Flotetuzumab Refractory AML (CD123 × CD3)
- Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms
- Risk Assessment and Risk Mitigation Review(S)
- Oncology Center of Excellence 2019 Annual Report
- PRECISION MEDICINE at the INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC
- Clinical Development
- JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
- Efficacy, Safety, and Survival with Ruxolitinib in Patients with Myelofibrosis: Results of a Median 3-Year Follow-Up of COMFORT-I John F
- Are Doses and Schedules of Small-Molecule Targeted
- Targeted Approaches to T-Cell Lymphoma
- Jakavi, INN-Ruxolitinib
- Ruxolitinib Cream
- Atopic Dermatitis: Beneath the Surface Individualizing Care for Patients with Moderate-To-Severe Disease
- Application of Janus Kinase Inhibitors in Atopic Dermatitis: an Updated Systematic Review and Meta-Analysis of Clinical Trials
- Rxoutlook® 1St Quarter 2021
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
- Perspectives on Interferon-Alpha in the Treatment of Polycythemia Vera and Related Myeloproliferative Neoplasms: Minimal Residual Disease and Cure?
- Risk Assessment and Risk Mitigation Review(S)
- Emetogenic Potential of Antineoplastic Agents
- Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms
- Selective Targeting of JAK/STAT Signaling Is Potentiated by Bcl-Xl Blockade in IL-2–Dependent Adult T-Cell Leukemia
- Publication Agenda CHMP 07-10 December 2020
- Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage
- S41467-021-21233-0.Pdf
- Mediated Inflammatory Diseases with Janus Kinase Inhibitors
- Jakavi® Tablets: 5 Mg, 10 Mg, 15 Mg and 20 Mg
- Optumrx Drug Pipeline Insights Report
- Janus Kinase Inhibitors in Myeloproliferative Neoplasms Clinical Applications
- Ruxolitinib) Tablets, for Oral Use and Initiate Appropriate Treatment Promptly
- Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
- Efficacy, Safety, and Survival with Ruxolitinib in Patients with Myelofibrosis: Results of a Median 3-Year Follow-Up of COMFORT-I